Fiona Heyes - Litigation Capital Head UnderwritingEMEA
| LIT Stock | 115.75 0.75 0.65% |
Executive
Fiona Heyes is Head UnderwritingEMEA of Litigation Capital Management
| Address | The Chifley Tower, Sydney, NSW, Australia, 2000 |
| Phone | 61 2 8098 1390 |
| Web | https://www.lcmfinance.com |
Litigation Capital Management Efficiency
The company has return on total asset (ROA) of 0.0832 % which means that it generated a profit of $0.0832 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0683 %, meaning that it generated $0.0683 on every $100 dollars invested by stockholders. Litigation Capital's management efficiency ratios could be used to measure how well Litigation Capital manages its routine affairs as well as how well it operates its assets and liabilities. At present, Litigation Capital's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 41 M, whereas Intangible Assets are forecasted to decline to about 289.8 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Charlotte Almberg | Coor Service Management | N/A | |
| Jeffrey Berkley | Surgical Science Sweden | 55 | |
| Markus Danielson | Coor Service Management | N/A | |
| Tom Englund | Surgical Science Sweden | 48 | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| BA FCA | Oncimmune Holdings plc | 56 | |
| Matthew Hall | Oncimmune Holdings plc | N/A | |
| Bo Kara | Mereo BioPharma Group | N/A | |
| Katarina Andersson | Coor Service Management | N/A | |
| Daniel Evestedt | Surgical Science Sweden | 47 | |
| Doron Zilberman | Surgical Science Sweden | 62 | |
| Sofia Nilsson | Coor Service Management | N/A | |
| BSc FRCP | Oncimmune Holdings plc | N/A | |
| Maarten Brusse | Oncimmune Holdings plc | N/A | |
| Christine CPA | Mereo BioPharma Group | 43 | |
| Fiona Bor | Mereo BioPharma Group | N/A | |
| Jens Rasmussen | Coor Service Management | 56 | |
| Cameron Barnard | Oncimmune Holdings plc | N/A | |
| Frida Sandgren | Coor Service Management | N/A | |
| Alexandra HughesWilson | Mereo BioPharma Group | 53 | |
| Anna Ahlberg | Surgical Science Sweden | 54 | |
Management Performance
| Return On Equity | 0.0683 | ||||
| Return On Asset | 0.0832 |
Litigation Capital Leadership Team
Elected by the shareholders, the Litigation Capital's board of directors comprises two types of representatives: Litigation Capital inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Litigation. The board's role is to monitor Litigation Capital's management team and ensure that shareholders' interests are well served. Litigation Capital's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Litigation Capital's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tobey Butcher, Investment EMEA | ||
| Kat Gieras, Business Manager | ||
| Susanna Taylor, Head APAC | ||
| Dip BSAB, CEO Director | ||
| Anna Sandham, Company Secretary | ||
| Fiona Heyes, Head UnderwritingEMEA | ||
| Mary Gangemi, CFO Director | ||
| David Collins, Chief Officer | ||
| Matthew Denney, Investment EMEA |
Litigation Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Litigation Capital a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0683 | ||||
| Return On Asset | 0.0832 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.68 % | ||||
| Current Valuation | (119.57 M) | ||||
| Shares Outstanding | 101.95 M | ||||
| Shares Owned By Insiders | 19.26 % | ||||
| Shares Owned By Institutions | 24.09 % | ||||
| Price To Book | 1.21 X | ||||
| Price To Sales | 1.19 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Litigation Stock
Litigation Capital financial ratios help investors to determine whether Litigation Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Litigation with respect to the benefits of owning Litigation Capital security.